ELLA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ella, and what generic alternatives are available?
Ella is a drug marketed by Lab Hra Pharma and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-five patent family members in twenty-eight countries.
The generic ingredient in ELLA is ulipristal acetate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Ella
Ella was eligible for patent challenges on August 13, 2014.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for ELLA
| International Patents: | 65 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 66 |
| Patent Applications: | 617 |
| Drug Prices: | Drug price information for ELLA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ELLA |
| What excipients (inactive ingredients) are in ELLA? | ELLA excipients list |
| DailyMed Link: | ELLA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ELLA
Paragraph IV (Patent) Challenges for ELLA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ELLA | Tablets | ulipristal acetate | 30 mg | 022474 | 1 | 2014-08-13 |
US Patents and Regulatory Information for ELLA
ELLA is protected by eight US patents and one FDA Regulatory Exclusivity.
Patents protecting ELLA
Method for on-demand contraception
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
Method for on-demand contraception
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
Method for providing emergency contraception
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
Ulipristal acetate tablets
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Ulipristal acetate tablets
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHTHAVING A BMI OF 25 TO 29.99
Method for on-demand contraception
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
Ulipristal acetate tablets
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting ELLA
REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDYHRA2914-5016
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ELLA
When does loss-of-exclusivity occur for ELLA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 09326084
Estimated Expiration: See Plans and Pricing
Canada
Patent: 45084
Estimated Expiration: See Plans and Pricing
China
Patent: 2245173
Estimated Expiration: See Plans and Pricing
Patent: 5267168
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 00186
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0161262
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 18099
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 65800
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 65800
Estimated Expiration: See Plans and Pricing
Patent: 03445
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 32134
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 30762
Estimated Expiration: See Plans and Pricing
Israel
Patent: 3247
Estimated Expiration: See Plans and Pricing
Japan
Patent: 84502
Estimated Expiration: See Plans and Pricing
Patent: 51727
Estimated Expiration: See Plans and Pricing
Patent: 12511041
Estimated Expiration: See Plans and Pricing
Patent: 15107994
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 65800
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 3358
Estimated Expiration: See Plans and Pricing
Patent: 11006106
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 3498
Estimated Expiration: See Plans and Pricing
Poland
Patent: 65800
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 65800
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 92853
Estimated Expiration: See Plans and Pricing
Patent: 11127989
Estimated Expiration: See Plans and Pricing
San Marino
Patent: 01600372
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 209
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 65800
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1104137
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1733533
Estimated Expiration: See Plans and Pricing
Patent: 110097936
Estimated Expiration: See Plans and Pricing
Spain
Patent: 96554
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 1863
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ELLA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 615430 | Method for on-demand contraception | See Plans and Pricing |
| Portugal | 2365800 | See Plans and Pricing | |
| Poland | 2419108 | See Plans and Pricing | |
| San Marino | T201600399 | METODO DI CONTRACCEZIONE A RICHIESTA | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
